Liglifev (Metformin Hydrochloride, Linagliptin)

Liglifev, combining metformin and linagliptin, is used in the management of type 2 diabetes mellitus.

• Type 2 diabetes mellitus: improves overall glycemic control as part of a comprehensive treatment plan.
• Monotherapy in patients inadequately controlled with diet and exercise: provides an oral option to achieve target HbA1c.
• Combination therapy with other antidiabetic agents: adds efficacy when used alongside sulfonylureas, insulin, or SGLT2 inhibitors.

• Metformin primarily decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, leading to reduced glucose output. Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4, which prolongs the activity of endogenous incretin hormones (GLP‑1 and GIP). The increased incretin effect promotes glucose‑dependent insulin secretion and suppresses glucagon release, resulting in lower post‑prandial and fasting blood glucose levels. Together, the two mechanisms provide complementary glucose‑lowering effects without causing hypoglycemia when used alone.

Liglifev may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: increased bowel movements, usually transient.
• Abdominal discomfort: cramps or pain in the abdomen.
• Headache: mild to moderate intensity.
• Dizziness: sensation of light‑headedness.
• Hypoglycemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal metabolic complication.
• Severe hypoglycemia: profound low glucose requiring assistance.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Acute allergic reactions: rash, angioedema, or anaphylaxis.
• Hepatic failure: signs of liver dysfunction.
• Renal impairment worsening: decline in kidney function.

When prescribing Liglifev, clinicians should consider several safety precautions to minimize risk.

• Renal function assessment: evaluate eGFR before initiating and periodically thereafter.
• Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
• Hypoglycemia monitoring: increase vigilance when used with insulin or sulfonylureas.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Drug interaction review: assess concomitant medications that may affect glucose or renal function.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Liglifev can interact with other medicines; understanding the level of interaction helps guide clinical decisions.

Major Interactions (Avoid)

• Insulin or sulfonylureas: increased risk of severe hypoglycemia.
• Iodinated contrast agents: may precipitate metformin‑associated renal dysfunction.
• Strong CYP3A4 inhibitors: can raise linagliptin plasma concentrations.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Beta‑blockers: may mask symptoms of hypoglycemia.
• Rifampicin: may reduce linagliptin exposure.
• Oral contraceptives: may slightly increase metformin levels.